Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Health care reform will lead more people to seek cancer prevention and risk-reduction services

More people will likely seek cancer prevention and risk-reduction services as a result of health care reform, say experts at The University of Texas MD Anderson Cancer Center.

19 Oct 2010

Increased colorectal cancer screening in pre-Medicare population can reduce program costs

Investment in screening programs that target the pre-Medicare population, individuals aged between 50 and 64, is needed to reduce the costs of colorectal cancer in the Medicare program, according to the results of a new study, "Cost-Savings to Medicare from Increased Colorectal Cancer Screening in the Pre-Medicare Population," unveiled today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.

19 Oct 2010

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

Many of the world's preeminent gastroenterologists will gather for the American College of Gastroenterology's (ACG) 75th Annual Scientific Meeting at the Henry B. Gonzalez Convention Center in San Antonio, Texas starting Monday October 18, 2010, to review the latest scientific advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.

19 Oct 2010

Study suggests disparity in colorectal cancer demographics and outcomes between various races

The latest colorectal cancer research presented at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio this week strengthens the growing body of evidence that suggests significant disparity in colorectal cancer (CRC) demographics and outcomes between various races.

19 Oct 2010

Fatalism may prevent Latinas from using cancer screening services

Fatalism may prevent women from Latin American descent Latinas from using cancer screening services, according to Karla Espinosa de los Monteros and Dr. Linda Gallo from San Diego State University in the US. Their review shows that women who are pessimistic about preventive health practices and disease outcomes are less likely to have been screened for cervical, breast and colorectal cancer. The research is published online in Springer's International Journal of Behavioral Medicine.

19 Oct 2010

Long-term use of statins reduces colorectal cancer risk

A systematic review of the medical literature supports the hypothesis that statins, cholesterol-lowering drugs used to prevent cardiac problems, are associated with reduced risk of colon and rectal cancers.

19 Oct 2010

Study quantifies impact of screening programs in pre-Medicare population

19 Oct 2010

Type 2 diabetes and insulin use associated with CRC risk in men, but not women

There is an association between type 2 diabetes mellitus and colorectal cancer (CRC) among men, but not women, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

19 Oct 2010

Statins reduce risk of colon and rectal cancers: Study

A systematic review of the medical literature supports the hypothesis that statins, cholesterol‐lowering drugs used to prevent cardiac problems, are associated with reduced risk of colon and rectal cancers. A comprehensive analysis by investigators at the University of Michigan at Ann Arbor, included 22 scientific studies with more than 2.5 million combined participants.

18 Oct 2010

Retroflexion in right colon increases yield of polyps in proximal colon

Research exploring the progression of colon polyps to colorectal cancer and evaluating techniques to improve polyp detection was among the clinical science presented at the 75th Annual Scientific Meeting of the American College of Gastroenterology in San Antonio today.

18 Oct 2010

Deductible-free screening encourages use of preventive care services

When they do not have to pay a health insurance deductible, people are more likely to undergo screening for conditions like cancer and high cholesterol. However, the increase is modest, and in high-deductible plans, it is quite small, according to a new study in the journal Health Services Research.

18 Oct 2010

Neogenix to present NPC-1C antibody data at ASCO Annual Meeting

Neogenix Oncology, Inc. announced today that it will present data from its new serum biomarker ELISA utilizing its NPC-1C antibody for patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Makers in Cancer, to be held in Hollywood, Florida from October 18-20, 2010.

18 Oct 2010

UK Intellectual Property Office issues patent for entinostat

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced the UK Intellectual Property Office allowed application GB0907347.9 entitled N-(2-aminophenyl)-4-[N-(pyridine-3-YL)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B.

18 Oct 2010

Study highlights need to address overuse, underuse of colorectal cancer screening tests

Only one-fifth of primary care physicians in the US follow practice guidelines for colorectal cancer screening for all the tests they recommend, according to Dr. Robin Yabroff from the National Cancer Institute and her colleagues. About 40 percent followed guidelines for some of the tests they recommended and the remaining 40 percent did not follow guidelines for any of the screening tests they recommended.

15 Oct 2010

Caris Life Sciences presents new diagnostic data at ACG 2010

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic technologies, today announced upcoming highlights from the Company's presentations at the 2010 Annual Meeting of the American College of Gastroenterology ("ACG 2010") held in San Antonio, TX, October 15-20. In total, Caris was awarded 17 accepted abstracts, three of which are ACG Presidential Poster Award recipients.

15 Oct 2010

Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer

A combination of Biothera's Imprime PGG and cetuximab (Erbitux) doubled the overall response rates for second- and third-line metastatic colorectal cancer patients participating in a Phase Ib/IIa clinical trial. The completed trial results were released yesterday at the 35th European Society for Medical Oncology (ESMO) Congress.

13 Oct 2010

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN and Abbott today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

From QIAGEN Manchester Limited 13 Oct 2010

Cancer patients getting unnecessary tests: Study

US researchers revealed that many cancer patients with only a few years to live often continue to get routine mammograms or blood tests for prostate cancer even though they are not likely to live long enough to benefit from them. This not only wastes money but also exposes patients to unnecessary worry and distress.

12 Oct 2010

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Merck Serono, a division of Merck KGaA, Darmstadt, Germany has announced that new data presented today at the 35th Congress of the European Society for Medical Oncology (ESMO) have shown that patients with KRAS wild-type metastatic colorectal cancer (mCRC) who experienced early tumor shrinkage (within 8 weeks) during 1st line Erbitux (cetuximab) based treatment lived a median of 28.3 months.

12 Oct 2010

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.

11 Oct 2010

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Health care reform will lead more people to seek cancer prevention and risk-reduction services

Increased colorectal cancer screening in pre-Medicare population can reduce program costs

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

Study suggests disparity in colorectal cancer demographics and outcomes between various races

Fatalism may prevent Latinas from using cancer screening services

Long-term use of statins reduces colorectal cancer risk

Study quantifies impact of screening programs in pre-Medicare population

Type 2 diabetes and insulin use associated with CRC risk in men, but not women

Statins reduce risk of colon and rectal cancers: Study

Retroflexion in right colon increases yield of polyps in proximal colon

Deductible-free screening encourages use of preventive care services

Neogenix to present NPC-1C antibody data at ASCO Annual Meeting

UK Intellectual Property Office issues patent for entinostat

Study highlights need to address overuse, underuse of colorectal cancer screening tests

Caris Life Sciences presents new diagnostic data at ACG 2010

Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

Cancer patients getting unnecessary tests: Study

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in